Still, information on clinical covariates and, in the best possible scenario, information on BRCA1, BRCA2, and CHEK2 (CHK2 checkpoint homolog [Schizosaccharomyces pombe]) might have allowed a deeper understanding of the biologic mechanisms by which prognostic outcome is determined by breast cancer survival among previously affected relatives. This evidence concerns the gene BRCA2 and breast carcinoma.